A New Application of Escobar: Gilead or When Half-Truths Can Become Actionable Under the FCA Read more
A Murky Future for Off-label Promotion: States vs. FDA – Arizona to Allow Pharma Companies to Legally Communicate Off- Label Treatment Options Read more
A Murky Future for Off-label Promotion: Off-Label Bills Garner Minimal Traction in Congress Read more